Elsie Biotechnologies
Martin Eastgate has been with Bristol Myers Squibb since June 2005, serving in various leadership roles, including Lead of Product Development at the BMS-Biocon Research Center, where collaboration across functions to enhance organization and strategy is emphasized. Active in the broader scientific community, Martin serves on the Scientific Advisory Board for Elsie Biotechnologies and Asymchem Group, as well as the Board of Directors for Organic Reactions Inc. Additionally, involvement with the Editorial Advisory Board for Organic Process Research and Development and fellowship with the Royal Society of Chemistry highlight ongoing contributions to the field. Martin's academic background includes a PhD from the University of Cambridge and a postdoctoral fellowship at the University of Illinois at Urbana-Champaign.
This person is not in any teams
This person is not in any offices
Elsie Biotechnologies
Elsie’s technology relies on a three dimensional platform that allows for the synthesis, deconvolution, and delivery of homogeneous oligonucleotide therapeutics. Our hope to leverage an out of the box way of thinking as well as a multidisciplinary approach to bring safer and more efficacious therapeutics to the market to treat the most intractable human diseases.